4162 Stock Overview
PharmaEngine, Inc., a biopharmaceutical company, engages in the development of drugs and therapeutic drugs for treating cancer in Taiwan and Europe.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 2/6 |
Rewards
Risk Analysis
No risks detected for 4162 from our risk checks.
PharmaEngine, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NT$90.70 |
| 52 Week High | NT$122.50 |
| 52 Week Low | NT$79.80 |
| Beta | 0.72 |
| 1 Month Change | -10.20% |
| 3 Month Change | -13.62% |
| 1 Year Change | -5.52% |
| 3 Year Change | 24.59% |
| 5 Year Change | -14.84% |
| Change since IPO | 47.57% |
Recent News & Updates
Recent updates
Would PharmaEngine, Inc. (GTSM:4162) Be Valuable To Income Investors?
Mar 30
How Much Did PharmaEngine's(GTSM:4162) Shareholders Earn From Share Price Movements Over The Last Five Years?
Feb 18Is PharmaEngine, Inc.'s (GTSM:4162) Stock On A Downtrend As A Result Of Its Poor Financials?
Jan 14
We're Not Counting On PharmaEngine (GTSM:4162) To Sustain Its Statutory Profitability
Dec 10Shareholder Returns
| 4162 | TW Biotechs | TW Market | |
|---|---|---|---|
| 7D | -2.1% | -0.7% | -1.6% |
| 1Y | -5.5% | -23.7% | 25.9% |
Return vs Industry: 4162 exceeded the TW Biotechs industry which returned -23.7% over the past year.
Return vs Market: 4162 underperformed the TW Market which returned 25.9% over the past year.
Price Volatility
| 4162 volatility | |
|---|---|
| 4162 Average Weekly Movement | 5.2% |
| Biotechs Industry Average Movement | 4.8% |
| Market Average Movement | 4.6% |
| 10% most volatile stocks in TW Market | 8.6% |
| 10% least volatile stocks in TW Market | 2.2% |
Stable Share Price: 4162 has not had significant price volatility in the past 3 months.
Volatility Over Time: 4162's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2002 | n/a | Hong-Ren Wang | www.pharmaengine.com |
PharmaEngine, Inc., a biopharmaceutical company, engages in the development of drugs and therapeutic drugs for treating cancer in Taiwan and Europe. It offers ONIVYDE, a novel and stable encapsulated chemotherapy drug irinotecan for the treatment of metastatic pancreatic cancer and other indications of clinical development. The company is developing PEP07, a checkpoint kinase 1 inhibitor, which is in preclinical development stage for the treatment of hematologic cancers and solid cancers, such as acute myeloid leukemia and mantle cell lymphoma.
PharmaEngine, Inc. Fundamentals Summary
| 4162 fundamental statistics | |
|---|---|
| Market cap | NT$13.03b |
| Earnings (TTM) | NT$274.65m |
| Revenue (TTM) | NT$767.67m |
47.4x
P/E Ratio17.0x
P/S RatioIs 4162 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4162 income statement (TTM) | |
|---|---|
| Revenue | NT$767.67m |
| Cost of Revenue | NT$48.70m |
| Gross Profit | NT$718.97m |
| Other Expenses | NT$444.32m |
| Earnings | NT$274.65m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Apr 25, 2024
| Earnings per share (EPS) | 1.91 |
| Gross Margin | 93.66% |
| Net Profit Margin | 35.78% |
| Debt/Equity Ratio | 0% |
How did 4162 perform over the long term?
See historical performance and comparison